PSTV earnings
PLUS THERAPEUTICS Inc. (PSTV) earnings releases and earnings dates - real-time wire coverage of every quarterly report.
Recent earnings items
- Plus Therapeutics Provides Business Update on REYOBIQ™ Clinical Program and U.S. CNSide® CommercializationHOUSTON, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) (the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today provides a business update and highlights REYOBIQ clinical progress and CNSide US commercialization. "Our 2 key goals in 2026 are CNSide commercial scale-up and REYOBIQ pivotal trial readiness," said Dr. Marc H. Hedrick, President & Chief Executive of Plus Therapeutics. "Our recently completed upsized $15 million offering will fuel faster progress in these core areas of the business and extend our cash runway through 2027." Overview of anticipated
- Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, January 22, 2026 at 9:00 A.M. ETHOUSTON, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) (the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announces that the Company will provide a business update on Thursday, January 22, 2026 before the market open. Plus Therapeutics' management team will then host a conference call and webcast at 9:00 a.m. ET to discuss and provide additional details. Webcast and Conference Call Date/Time:Thursday, January 22, 2026 @ 9:00 AM ETWebcast:https://event.choruscall.com/mediaframe/webcast.html?webcastid=x5QZCyIkParticipant Dial-in:1-888-349-0106 Please di
- Plus Therapeutics Reports Third Quarter Financial Results and Recent Business HighlightsUS market introduction of the CNSide® CSF diagnostics platform, with first national coverage agreement with UnitedHealthcare Presented positive RESPECT-LM Ph1 clinical trial results HOUSTON, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) ("Plus" or the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces financial results for the third quarter ended September 30, 2025 and provides an overview of recent and upcoming business highlights. "Our team continues to execute solidly across the three most important business verticals: diagnost
- Plus Therapeutics Reports Second Quarter Financial Results and Recent Business HighlightsAnnounced CNSide® CSF assay platform launch timeline Initiated the REYOBIQ dose optimization trial for patients with leptomeningeal metastases HOUSTON, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces financial results for the second quarter ended June 30, 2025, and provides an overview of recent and upcoming business highlights. "The second quarter of 2025 marked steady execution and progress on our key strategic initiatives: clinical development o
- Plus Therapeutics Provides Business Update on CNSide Diagnostics SubsidiaryU.S. commercial rollout of novel diagnostic platform to begin second half 2025 Underserved CNS cancer diagnostic U.S. market opportunity estimated to be in excess of $6 billion Management to host a conference call today at 9am ET HOUSTON, June 26, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, will provide a business update for its wholly-owned subsidiary, CNSide Diagnostics, LLC ("CNSide"). The proprietary CNSide Cerebrospinal Fluid (CSF) Assay Platform is designed and intended for patients s
- Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, June 26, 2025 at 9:00 A.M. ETHOUSTON, June 25, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces that the Company will provide a business update on Thursday, June 26, 2025 before the market open. Plus Therapeutics' management team will then host a conference call and webcast at 9:00 a.m. ET to discuss and provide additional details. Webcast and Conference Call Date/Time:Thursday, June 26, 2025 @ 9:00 AM ET Webcast: https://edge.media-server.com/mmc/p/97egitn8 Dial-in Link: https://register-conf.media-server.com/re
- Plus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business HighlightsHOUSTON, March 27, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces financial results for the fourth quarter and full year ended December 31, 2024, and provides an overview of recent and upcoming business highlights. "Over the last twelve months, Plus has reported very promising safety and efficacy data for our lead drug REYOBIQ administered in our two most advanced CNS cancer programs," said Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer. "The rece
- Plus Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 27, 2025HOUSTON, March 19, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces that the Company will report fourth quarter and full year 2024 financial results on Thursday, March 27, 2025 after market close. Plus Therapeutics' management team will then host a conference call and webcast at 5:00 p.m. ET to discuss the financial results and provide a corporate update. Webcast and Conference Call Date/Time:Thursday, March 27, 2025 @ 5:00 PM ETWebcast:https://edge.media-server.com/mmc/p/5r5hkcqqDial-in
- Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business HighlightsObtained agreement from FDA to initiate a Phase 1 trial evaluating multiple doses of Rhenium (186Re) Obisbemeda for the treatment of patients with leptomeningeal metastases (LM) Presented positive ReSPECT-GBM Trial Data at the 2024 Congress of Neurological Surgeons Annual Conference Established Radiotherapeutic Manufacturing Partnership with SpectronRx to meet late-stage clinical and commercial forecasts for Rhenium (186Re) Obisbemeda AUSTIN, Texas, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) ca
- Plus Therapeutics to Announce Third Quarter Financial Results and Host Conference Call on November 14, 2024AUSTIN, Texas, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that the Company will report third quarter 2024 financial results on Thursday, November 14, 2024, after market close. Plus Therapeutics' management team will then host a conference call and webcast at 5:00 p.m. ET to discuss the financial results and provide a corporate update. Webcast and Conference Call Date/Time:Thursday, November 14, 2024 @ 5:00 PM ETWebcast:https://edge.media-server.com/mmc/p/rdthwekoDial-in Link:http
- Plus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business HighlightsPresented Positive Interim ReSPECT-LM Phase 1 Data for Rhenium (186Re) Obisbemeda for Leptomeningeal MetastasesPresented Positive Topline Clinical Trial Results for CNSide diagnostic in the FORESEE trialManagement to host conference call August 14, 2024 at 5:00 p.m. ET AUSTIN, Texas, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced financial results for the second quarter ended June 30, 2024, and provided an overview of recent and upcoming business highlights. Q2 2024 RECENT HIG
- Plus Therapeutics to Announce Second Quarter Financial Results and Host Conference Call on August 14, 2024AUSTIN, Texas, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that the Company will report second quarter 2024 financial results on Wednesday, August 14, 2024, after market close. Plus Therapeutics' management team will then host a conference call and webcast at 5:00 p.m. ET to discuss the financial results and provide a corporate update. Webcast and Conference CallDate/Time:Wednesday, August 14, 2024 @ 5:00 PM ETWebcast:https://edge.media-server.com/mmc/p/mtnrwhh5Dial-in Link:https:/
- Plus Therapeutics Reports First Quarter 2024 Financial Results and Recent Business HighlightsAnnounced private placement of up to $19.25M with healthcare funds and insiders Received $3M award recommendation from the Department of Defense to support Plus' clinical brain cancer program Acquired synergistic leptomeningeal metastases diagnostic portfolio and announced related positive top-line FORESEE clinical trial data Management to Host Conference Call May 15, 2024 at 5:00 p.m. ET AUSTIN, Texas, May 15, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous
- Plus Therapeutics to Announce First Quarter Financial Results and Host Conference Call on May 15, 2024AUSTIN, Texas, May 13, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that the Company will report first quarter 2024 financial results on Wednesday, May 15, 2024, after market close. Plus Therapeutics' management team will then host a conference call and webcast at 5:00 p.m. ET to discuss the financial results and provide a corporate update. Webcast and Conference CallWednesday, May 15, 2024 @ 5:00 PM ETDial-in Link: https://register.vevent.com/register/BI7282c3e944b0498483eb5b57757ccaad
- Plus Therapeutics to Host Investor Call to Discuss Leptomeningeal Cancer Related Acquisition and Topline Clinical Trial Data from the FORESEE TrialCompany acquired all assets for the synergistic CNSide cerebrospinal fluid diagnostic portfolio Company will summarize topline data from the FORESEE clinical trial planned for presentation at the SNO/ASCO Meeting in August 2024 Management call scheduled for Thursday, May 9th, 2024 at 8:30 AM ET AUSTIN, Texas, May 08, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces it will host an investor call on Thursday, May 9th, 2024 at 8:30 AM ET to discuss the strategic acquisition of the
- Plus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business HighlightsBegan enrollment of the 5th of an anticipated 7 planned dosing cohorts for the ReSPECT-LM Phase 1 dose escalation trial with rhenium (186Re) obisbemeda for leptomeningeal metastases (LM) Reached agreement to expand ReSPECT-GBM Phase 2 trial and add new sites Current financial forecast for sufficient runway to fund operations into 2H 2025 Management to Host Conference Call March 5, 2024 at 5:00 p.m. ET AUSTIN, Texas, March 05, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced financial result
- Plus Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on March 5, 2024AUSTIN, Texas, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that the Company will report fourth quarter and full year 2023 financial results on Tuesday, March 5, 2024, after market close. Plus Therapeutics' management team will then host a conference call and webcast at 5:00 p.m. ET to discuss the financial results and provide a corporate update. Conference Call & Webcast Tuesday, March 5, 2024 @ 5:00 PM ET Dial-in Link:https://register.vevent.com/register/BIa3e26b40a05b4e7185cb3d97
- Plus Therapeutics Reports Third Quarter 2023 Financial Results and Business HighlightsNew survival data from 15 patients in the Phase 2 ReSPECT-GBM trial of rhenium (186Re) obisbemeda in recurrent glioblastoma (rGBM) will be presented at SNO Annual Meeting on November 17th; Company will also host a Key Opinion Leader (KOL) event following the meeting to discuss the results Completed dosing in Cohort 4 of the Phase 1 ReSPECT-LM dose escalation trial with rhenium (186Re) obisbemeda for leptomeningeal metastases, the first of four additional planned cohorts in Part B (Cohorts 4-7); an update will also be provided at the SNO meeting in November Current cash of $11 million, plus an additional $10.2 million expected through the end of 2024 from the Cancer Prevention & Res
- Plus Therapeutics to Announce Third Quarter 2023 Financial Results and Host Conference Call on October 31, 2023AUSTIN, Texas, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that the Company will report third quarter 2023 financial results on Tuesday, October 31, 2023, after market close. Plus Therapeutics' management team will then host a conference call and webcast at 5:00 p.m. ET to discuss the financial results and provide a corporate update. Conference Call & WebcastTuesday, October 31, 2023 @ 5:00 PM ETDial in #:https://register.vevent.com/register/BI484eba10ce0d4bc292c51db6fc396f0cWebcas
- Plus Therapeutics Reports Second Quarter 2023 Financial Results and Business HighlightsReSPECT clinical trial data continues to demonstrate promise for treatment of leptomeningeal metastases and recurrent glioblastoma Received FDA approval to move into Phase 1/Part B of the ReSPECT-LM clinical trial Management to host conference call today at 5:00 p.m. ET AUSTIN, Texas, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced financial results for the second quarter ended June 30, 2023, and provided an overview of recent business highlights. "The past 12 months have been tra
- Plus Therapeutics to Announce Second Quarter 2023 Financial Results and Host Conference Call on August 14, 2023AUSTIN, Texas, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult to treat cancers, announced that the Company will report second quarter 2023 financial results on Monday, August 14, 2023, after market close. Plus Therapeutics' management team will then host a conference call and webcast at 5:00 p.m. ET to discuss the financial results and provide a corporate update. A live webcast will be available at ir.plustherapeutics.com/events. Participants may also pre-register any time before the call here. Once registration is completed, particip
- Plus Therapeutics Reports First Quarter 2023 Financial Results and Business HighlightsPlus completes Phase 1/Part A of the ReSPECT-LM trial Management to host conference call today at 5:00 p.m. ET AUSTIN, Texas, April 20, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced financial results for the first quarter ended March 31, 2023, and provided an overview of recent business highlights. "Our team has continued the strong momentum from 2022 through the first quarter of 2023," said Marc H. Hedrick M.D., President and Chief Executive Officer of Plus Therapeutics. "Our 2023 focus
- Plus Therapeutics to Announce First Quarter 2023 Financial Results and Host Conference Call on April 20, 2023AUSTIN, Texas, April 12, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult to treat cancers, announced that the Company will report first quarter 2023 financial results on Thursday, April 20, 2023, after market close. Plus Therapeutics' management team will then host a conference call and webcast at 5:00 p.m. ET to discuss the financial results and provide a corporate update. A live webcast will be available at ir.plustherapeutics.com/events. Participants may also pre-register any time before the call here. Once registration is completed, par
- Plus Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business HighlightsInitiated ReSPECT-GBM Phase 2 and ReSPECT- LM Phase 1 trials for CNS cancers Awarded $17.6 million Cancer Prevention & Research Institute of Texas (CPRIT) grant to support clinical development of rhenium (186Re) obisbemeda for leptomeningeal metastases (LM) Cash, grant funding, and discretionary capital sources expected to be sufficient to fund expenses through 2025 Management to host conference call today at 5:00 p.m. ET AUSTIN, Texas, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announc
- Plus Therapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 23, 2023AUSTIN, Texas, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult to treat cancers, announced that the Company will report fourth quarter and full year 2022 financial results on Thursday, February 23, 2023, after market close. Plus Therapeutics' management team will then host a conference call and webcast at 5:00 p.m. ET to discuss the financial results and provide a corporate update. A live webcast will be available at ir.plustherapeutics.com/events. Participants may also pre-register any time before the call here. Once registration is c
- Plus Therapeutics Reports Third Quarter 2022 Financial Results and Business HighlightsAwarded $17.6 million Product Development Research grant by the Cancer Prevention & Research Institute of Texas (CPRIT) to fund 186RNL development for leptomeningeal metastases (LM) Completed cGMP manufacturing objectives to support Phase 2 clinical trials for 186RNL Initiating ReSPECT-GBM Phase 2 trial for recurrent glioblastoma (GBM) in Q4 2022 Management to host conference call today at 5:00 p.m. ET AUSTIN, Texas, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cance
- Plus Therapeutics to Announce Third Quarter 2022 Financial Results and Host Conference Call on October 20, 2022AUSTIN, Texas, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult to treat cancers, announced that the Company will report third quarter 2022 financial results on Thursday, October 20, 2022, after market close. Plus Therapeutics' management team will then host a conference call and webcast at 5:00 p.m. ET to discuss the financial results and provide a corporate update. A live webcast will be available at ir.plustherapeutics.com/events. Participants may also pre-register any time before the call here. Once registration is completed
- Plus Therapeutics Reports Second Quarter 2022 Financial Results and Business HighlightsCompleted enrollment of Cohort 1 in ReSPECT-LM Phase 1/2a dose escalation trial of 186RNL for Leptomeningeal Metastases On track to complete key manufacturing objectives for cGMP 186RNL to support ongoing and planned clinical trials in 2022 and beyond Multiple planned data presentations for glioblastoma and leptomeningeal metastasis indications planned for the second half of 2022 Management to host conference call today at 5:00 p.m. ET AUSTIN, Texas, July 21, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced fi
- Plus Therapeutics to Announce Second Quarter 2022 Financial Results and Host Conference Call on July 21, 2022AUSTIN, Texas, July 13, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult to treat cancers, announced that the Company will report second quarter 2022 financial results on Thursday, July, 21, 2022, after market close. Plus Therapeutics' management team will then host a conference call and webcast at 5:00 p.m. ET to discuss the financial results and provide a corporate update. A live webcast will be available at ir.plustherapeutics.com/events. Participants may also pre-register any time before the call here. Once registration is completed, partici
- Plus Therapeutics Reports First Quarter 2022 Financial Results and Business HighlightsFirst patient dosed in ReSPECT-LM Phase 1/2a dose escalation trial of 186RNL for leptomeningeal metastases Closed in-licensing transaction for novel targeted radioembolic technology for the treatment of solid organ tumors Expanded ReSPECT-GBM clinical trial partnership with Medidata to design innovative registrational trial of 186RNL for recurrent glioblastoma Management to host conference call today at 5:00 p.m. ET AUSTIN, Texas, April 21, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing innovative, targeted radiothe
- Plus Therapeutics to Announce First Quarter 2022 Financial Results and Host Conference Call on April 21, 2022AUSTIN, Texas, April 14, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult to treat cancers, announced that the Company will report first quarter 2022 financial results on Thursday, April, 21, 2022, after market close. Plus Therapeutics' management team will then host a conference call and webcast at 5:00 p.m. ET to discuss the financial results and provide a corporate update. A live webcast will be available at ir.plustherapeutics.com/events Please refer to the information below for conference call dial-in information. Callers should dial in
- Plus Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Business HighlightsExpanded pipeline with recently licensed targeted interventional radiotherapeutics platform Announced positive interim data from ReSPECT-GBM Phase 1 clinical trial Management to host conference call today at 5:00 p.m. ET AUSTIN, Texas, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced financial results for the fourth quarter and full year ended December 31, 2021, and provided an overview of recent business highlights. "In 2021, the Company significantly advanced its lead 186RNL program and expanded it
- Plus Therapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on February 24, 2022AUSTIN, Texas, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult to treat cancers, announced that the Company will report fourth quarter and full year 2021 financial results on Thursday, February 24, 2022, after market close. Plus Therapeutics' management team will then host a conference call and webcast at 5:00 p.m. ET to discuss the financial results and provide a corporate update. A live webcast will be available at ir.plustherapeutics.com/events Please refer to the information below for conference call dial-in information. Callers
- Plus Therapeutics Reports Third Quarter 2021 Financial Results and Business HighlightsAUSTIN, Texas, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced financial results for the third quarter ended September 30, 2021, and provided an overview of recent business highlights. "In the third quarter, we made meaningful progress executing our strategy to develop novel radiotherapeutics for rare and central nervous system cancers," said Marc H. Hedrick M.D., President and Chief Executive Officer of Plus Therapeutics. "We increased the ReSPECT-GBM™ trial dose by 40%, were accepted to present an upd
- Plus Therapeutics to Announce Third Quarter 2021 Financial Results and Host Conference Call on October 21, 2021AUSTIN, Texas, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult to treat cancers, announced that the Company will report third quarter 2021 financial results on Thursday, October 21, 2021, after market close. Plus Therapeutics' management team will then host a conference call and webcast at 5:00 p.m. ET to discuss the financial results and provide a corporate update. A live webcast will be available at ir.plustherapeutics.com/events Please refer to the information below for conference call dial-in information. Callers should dial in
- Plus Therapeutics Reports Second Quarter 2021 Financial Results and Business HighlightsAUSTIN, Texas, July 22, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced financial results for the second quarter ended June 30, 2021, and provided an overview of recent business highlights. "Our focus remains on completion of our Phase 1 dose escalation ReSPECT™-GBM trial, which is evaluating the Company's lead investigational drug, Rhenium-186 NanoLiposome (186RNL) in recurrent glioblastoma (GBM), expansion of our 186RNL pipeline, and GMP production of 186RNL to be available in mid-2022 for a potential registra